

SynAct Pharma announces program for the upcoming Capital Markets Day in Stockholm on May 5, 2023

SynAct Pharma AB (publ) ("SynAct") today announced the program for the upcoming Capital Markets Day in Stockholm on May 5, 2023, for investors, analysts and media. The Capital Markets Day will feature presentations from SynAct's management team and pre-clinical and clinical experts to provide an in-depth overview of the company's development programs.

The agenda will be as follows:

Program		
13:00	Introduction	CEO Jeppe Øvlesen
	Corporate update	Chairman Torbjørn Bjerke
13:15	Melanocortin receptors and inflammation resolution	Professor Mauro Perretti
	SynAct pre-clinical MC peptides	CSO Thomas Jonassen
	<i>Q&A Session (break after QA session)</i>	
14:30	AP1189 program updates	CSO Thomas Jonassen
	Unmet needs in RA around DMARD therapies	Rheumatologist Clinician
	AP1189 positioning and opportunity in RA and beyond	CBO Jim Knight
	<i>Q&A Session</i>	
	Wrap-up – SynAct on the move	Chairman Torbjørn Bjerke
16:00	Reception	

The Capital Markets Day will be held at GT30 Grev Ture in Stockholm and be accessible through a webcast via the company's website and via <https://financialhearings.com/event/46621>. The program will be held in English and run from 13:00 to 16:00 CEST. The presentations will be available on the company's website after the event.

If you wish to attend, please register now via email to: investor.relations@synactpharma.com.

The information was submitted, through the agency of the contact person below, for publication at 08:00 a.m CEST on April 17, 2023

Attachments

[SynAct Pharma announces program for the upcoming Capital Markets Day in Stockholm on May 5, 2023](#)